Vibrato Medical Closes $4M Series A Funding Round and Receives $1.5M NIH Grant
- Vibrato Medical
MONTIRVINE, Calif.–(BUSINESS WIRE)–Vibrato Medical, an innovator in the treatment of peripheral arterial disease (PAD), announced today that it has closed a $4M Series A funding round led by the Horowitz Group, a multi-asset class family investment office based in Newport Beach, CA, and has also received a $1.5M National Institutes of Health (NIH) grant. Together, funding will support the clinical trial of the company’s novel, noninvasive, wearable device designed to treat patients with critical limb ischemia (CLI), an advanced stage of PAD, from the convenience of their home. Read more…
Related Reading
Resource / Regulatory Affairs
Successful Market Access of SaMD & MDSW: Decoding the Confusion in MedTech Software Development
April 12, 2024
Artificial intelligence has been in the spotlight recently, but it is not a new concept to the Food and Drug Administration (FDA) or the medtech industry. AI advancements in the medtech industry are playing a major role in improving patients’ lives through innovative care, reduced healthcare costs, and improved patient outcomes.
News / Coverage & Payment
AdvaMed to CMS: “1,138 Days Without Breakthrough Coverage is Harming Seniors”
April 11, 2024
AdvaMed, the Medtech Association, unveiled a timer on the organization’s website to track the number of days since the Centers for Medicare and Medicaid Services (CMS) ended the coverage pathway for FDA-approved breakthrough medical devices.
Event / Coverage & Payment
AdvaMed Payment Policy Forum
May 21, 2024: 8:15 AM – 4:15 PM ET
May 22, 2024: 8:15 AM – 12:00 PM ET
Gain insights from leaders from CMS and industry experts as they delve into medtech payment policies, private payer challenges and more.
Resource / Regulatory Affairs
PFAS in Medtech
March 8, 2024
Event / Coverage & Payment
101 Workshop: MedTech Coverage, Coding and Reimbursement
May 13, 2024: 12:00 PM – 3:15 PM ET
May 14, 2024: 12:00 PM – 3:30 PM ET
Learn the basic principles of how medical technologies are covered and paid by insurers and the challenges medtech companies face.
News / Ethylene Oxide / Regulatory Affairs
AdvaMed Anticipates EtO Sterilization Rule, Voices Concern About Impact on Patient Care
February 27, 2024
By Friday, March 1, the Environmental Protection Agency is expected to finalize its regulation for the ethylene oxide (EtO) sterilization of 20 billion, or half, of all medical devices in the United States each year. AdvaMed President and CEO Scott Whitaker released the following statement:
Resource / Regulatory Affairs
Artificial Intelligence in Medtech
February 21, 2024
Artificial intelligence has been in the spotlight recently, but it is not a new concept to the Food and Drug Administration (FDA) or the medtech industry. AI advancements in the medtech industry are playing a major role in improving patients’ lives through innovative care, reduced healthcare costs, and improved patient outcomes.
Resource / Regulatory Affairs
Artificial Intelligence in Medical Technology Myths and Facts
February 21, 2024
Outlining the facts and dispelling myths will inform policymaking to avoid overlap with current regulations and preserve the broad capacity of innovation to help patients.